Representative before the EPO

Technology company logo thumb
no operation time available
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Employment test 51 - 200 employees
Company dna mathys and squire llp
no operation time available
Headquarter in London and 5 offices
active in Legal Services and Matchmaking and Trading

Paul Martin Brial Commander has worked on the following 9 EPO patent applications which have been published in the last five years:

EP11192672

Immunisation method against the 4 Dengue serotypes

IPC classification:
A61K 39/12, A61P 31/14
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Mathys & Squire LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13183819

Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses

IPC classification:
A61K 39/12
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13740025

VACCINE COMPOSITIONS FOR PREVENTION AGAINST DENGUE VIRUS INFECTION

IPC classification:
A61K 39/12, A61K 39/295
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
GRANT OF PATENT INTENDED
EP13741748

VACCINE COMPOSITIONS

IPC classification:
A61K 39/12, A61K 39/295
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
GRANT OF PATENT INTENDED
EP13774363

VACCINATION AGAINST JAPANESE ENCEPHALITIS, MEASLES, MUMPS AND RUBELLA

IPC classification:
A61K 39/295, A61P 31/14
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
EXAMINATION IN PROGRESS
EP13163182

AAV virions with decreased immunoreactivity and uses therefor

IPC classification:
C07K 1/00, C07K 14/00, C07K 14/015, C07K 17/00, C12N 15/00, C12N 15/09, C12N 15/63, C12N 15/70, C12N 15/74, C12N 15/864
Agent:
Multiple attorneys, Mathys & Squire LLP
Status:
PATENT GRANTED
EP13163168

AAV virions with decreased immunoreactivity and uses therefor

IPC classification:
C07K 1/00, C07K 14/00, C07K 14/015, C07K 17/00, C12N 15/00, C12N 15/09, C12N 15/63, C12N 15/70, C12N 15/74, C12N 15/864
Applicant:
Genzyme Corporation
Agent:
Multiple attorneys, Mathys & Squire LLP
Status:
PATENT GRANTED
EP11192665

Immunisation method against the 4 Dengue serotypes

IPC classification:
A61K 39/12, A61P 31/14
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Mathys & Squire LLP
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP15759746

VACCINE COMPOSITIONS AGAINST DENGUE VIRUS DISEASES

IPC classification:
A61K 39/00, A61K 39/12, A61K 39/295
Applicant:
Sanofi Pasteur SA
Agent:
Paul Martin Brial Commander, Sanofi Pasteur SA
Status:
Request for examination was made

Please Sign in to use this feature